Product Description
Paroxetine is a potent and selective serotonin reuptake inhibitor (SSRI) with currently approved indications for the treatment of depression, obsessive-compulsive disorder, panic disorder and social phobia. It is also used in the treatment of generalized anxiety disorder, post traumatic stress disorder, premenstrual dysphoric disorder and chronic headache. Paroxetine, a phenylpiperidine derivative, is the most potent inhibitor of the reuptake of serotonin (5-hydroxytryptamine, 5-HT) of all the currently available antidepressants including the class of SSRIs. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11420571/)
Mechanisms of Action: SSR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Generalized anxiety disorder | Obsessive-Compulsive Disorder | Panic Disorder | Depressive Disorder | Depressive Disorder, Major | Stress Disorders, Post-Traumatic | Premenstrual Dysphoric Disorder | Menopause | Generalized anxiety disorder | Obsessive-Compulsive Disorder | Panic Disorder | Depressive Disorder | Depressive Disorder, Major
Known Adverse Events: Dizziness | Tremor | Insomnia | Asthenia | Constipation | Diarrhea | Headache
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Korea, Netherlands, United Kingdom
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Generalized anxiety disorder|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ASN51-104 | P1 |
Completed |
Healthy Volunteers |
2024-07-03 |
|
| NCT06065735 | P1 |
Completed |
Generalized anxiety disorder|Healthy Volunteers |
2024-01-08 |
|
| DA8010_DIPM_I | P1 |
Completed |
Healthy Volunteers |
2023-11-07 |
28% |
| DA8010_DIPM_I | P1 |
Completed |
Healthy Volunteers |
2023-11-07 |
28% |